These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 31914963)

  • 1. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
    Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
    BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
    Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
    N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
    Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
    Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung function outcomes in the INPULSIS
    Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
    Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
    Flaherty KR; Kolb M; Vancheri C; Tang W; Conoscenti CS; Richeldi L
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup Analysis for Chinese Patients Included in the INPULSIS
    Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
    Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.
    Kreuter M; Koegler H; Trampisch M; Geier S; Richeldi L
    Respir Res; 2019 Apr; 20(1):71. PubMed ID: 30971229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
    Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
    Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subgroup analysis of Asian patients in the INPULSIS
    Taniguchi H; Xu Z; Azuma A; Inoue Y; Li H; Fujimoto T; Bailes Z; Schlenker-Herceg R; Kim DS
    Respirology; 2016 Nov; 21(8):1425-1430. PubMed ID: 27399197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.
    Richeldi L; Crestani B; Azuma A; Kolb M; Selman M; Stansen W; Quaresma M; Stowasser S; Cottin V
    Respir Med; 2019 Sep; 156():20-25. PubMed ID: 31404749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
    Song JW; Ogura T; Inoue Y; Xu Z; Quaresma M; Stowasser S; Stansen W; Crestani B
    Respirology; 2020 Apr; 25(4):410-416. PubMed ID: 31329360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
    Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
    Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
    Behr J; Kolb M; Song JW; Luppi F; Schinzel B; Stowasser S; Quaresma M; Martinez FJ
    Am J Respir Crit Care Med; 2019 Dec; 200(12):1505-1512. PubMed ID: 31365829
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
    Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
    Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
    Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Valenzuela C; Wijsenbeek M; Kreuter M; Stansen W; Quaresma M; Cottin V
    Respir Res; 2020 Nov; 21(1):312. PubMed ID: 33239000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
    Kolb M; Raghu G; Wells AU; Behr J; Richeldi L; Schinzel B; Quaresma M; Stowasser S; Martinez FJ;
    N Engl J Med; 2018 Nov; 379(18):1722-1731. PubMed ID: 30220235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
    Azuma A; Taniguchi H; Inoue Y; Kondoh Y; Ogura T; Homma S; Fujimoto T; Sakamoto W; Sugiyama Y; Nukiwa T
    Respirology; 2017 May; 22(4):750-757. PubMed ID: 27997064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
    Costabel U; Inoue Y; Richeldi L; Collard HR; Tschoepe I; Stowasser S; Azuma A
    Am J Respir Crit Care Med; 2016 Jan; 193(2):178-85. PubMed ID: 26393389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
    Kolb M; Richeldi L; Behr J; Maher TM; Tang W; Stowasser S; Hallmann C; du Bois RM
    Thorax; 2017 Apr; 72(4):340-346. PubMed ID: 27672117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.